Immediate-release (IR) tablets: 250 to 1000 mg orally per day amounts over 250 mg should be administered in divided doses.Įxtended-release (ER) capsules: 500 mg orally 2 times a day. Guideline dose (immediate release): 2.5 mg/kg orally every 12 hours. It is preferable to initiate dosing 24 to 28 hours before ascent and to continue for 48 hours while at high altitude, or longer as necessary to control symptoms.Įxtended-release capsules: 500 mg orally once or twice a day. In circumstances of rapid ascent, such as in rescue or military operations, the higher dose level of 1000 mg is recommended.

Acetazolamide yields best diuretic results when given on alternate days, or for two days alternating with a day of rest.ĭosage is 500 mg to 1000 mg daily, in divided doses using tablets or sustained-release capsules as appropriate. If after an initial response, the patient fails to continue to lose edema fluid, do not increase the dose but allow for kidney recovery by skipping medication for a day. Maintenance dose: One dose every other day or once a day for 2 days alternating with a day of rest.įor diuresis in congestive heart failure, the starting dose is usually 250 to 375 mg once daily in the morning (5 mg/kg). If after initial response there is a lack of response, hold therapy for a day Initial dose: 250 to 375 mg orally/IV once a day The Tmax was found within 1-4 hours (by mouth), 8-18 hour (by Capsule), and 15 min (Intravenous) following the administration of Acetazolamide. The Duration of Action for Acetazolamide in the body is approximately 8-12 hours (by Tablet), 18-24 hour (by Capsule), and 4-5 hours (by Intravenous). The onset of action of Acetazolamide occurs within 1-1.5 hour (by Tablet), 2 hour (by Capsule), and 5-10min (by Intravenous). This leads to alkaline urine and an increase in the excretion of bicarbonate, sodium, potassium, and water. The diuretic effect depends on the inhibition of carbonic anhydrase, causing a reduction in the availability of hydrogen ions for active transport in the renal tubule lumen. The anticonvulsant activity of Acetazolamide may depend on a direct inhibition of carbonic anhydrase in the CNS, which decreases carbon dioxide tension in the pulmonary alveoli, thus increasing arterial oxygen tension. Renal excretion is the primary route of elimination about 90% is excreted by urine.Īcetazolamide shows common side effects like Diarrhoea, Vomiting, Loss of appetite, Numbness, tingling in arms or legs, Increased thirst, Increased urination frequency, Drowsiness, Headache, Fever and cough, yellowing of skin and eyes, Sore throat, unusual bleeding or bruising, altered blood glucose levels, change in taste/ Metallic taste, Decrease in sexual drive, etc.Īcetazolamide is available in the form of Oral Tablets, Oral Capsule and Powder for Injection.Īcetazolamide is available in India, US, UK, Canada, Singapore, China, Japan and Australia.Īcetazolamide belonging to the Carbonic Anhydrase Inhibitor, acts as an antihypertensive agent. Plasma half-Life found to be approximately 6-9 hours. Acetazolamide does not undergo metabolic alteration. Carbonic anhydrase inhibitors such as acetazolamide are avidly bound by carbonic anhydrase consequently, tissues rich in enzymes, such as kidneys and RBC, will have higher concentrations of carbonic anhydrase inhibitors (acetazolamide). Acetazolamide is highly bound to plasma protein about 98%. CDSCO (Central Drugs Standard Control Organisation) NewsĪcetazolamide is an antihypertensive agent belonging to Carbonic Anhydrase Inhibitor.Īcetazolamide is a carbonic anhydrase inhibitor used to treat edema from heart failure or medications, certain types of epilepsy, and glaucoma.Īcetazolamide is well absorbed.

Diamox antidote for aspirin